Login to Your Account


Speedel Begins Pivotal Trial Of SPP301 In Diabetic Nephropathy

By Jennifer Boggs


Wednesday, July 13, 2005
Four months after reporting positive results from a Phase IIb trial of its endothelin A receptor antagonist, SPP301, in diabetic nephropathy, Speedel Group AG initiated a pivotal Phase III study in Type II diabetes patients. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription


»

For Sales Inquiries,
http://clarivate.com/life-sciences/news/bioworld/#

 
Privacy Policy | Terms of Use | Copyright
 
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Clarivate Analytics